Showing recent highlights
Medications
PubMed · December 1, 2026
This research looked at two blood thinners — Eliquis (apixaban) and Xarelto (rivaroxaban) — compared to an older blood thinner called warfarin, in people who have atrial fibrillation (an irregular heartbeat that raises stroke risk) and are on dialysis due to serious kidney disease. The study found that Eliquis and Xarelto were linked to lower rates of dangerous bleeding, stroke, and death compared to warfarin in this group, which is a meaningful safety and effectiveness update for a population that has historically been very difficult to treat. This adds to a growing picture suggesting these newer blood thinners may be a safer option than warfarin for people in this specific situation, though your doctor would weigh all the details before making any decision.
Ask your doctor: Ask the doctor whether apixaban might be safer than warfarin for preventing blood clots if the patient have atrial fibrillation and kidney problems.
What's New
PubMed · December 1, 2026
Researchers found something surprising: smartwatches and wearable heart monitors were very good at spotting atrial fibrillation — an irregular heartbeat that can raise the risk of serious heart problems like heart attacks or strokes — but finding more cases didn't actually seem to lead to better health outcomes for people screened. In fact, continuous monitoring nearly tripled the number of diagnoses and doubled the use of blood-thinning medications, yet the extra treatment didn't clearly prevent harm, raising the question of whether some of those diagnoses may not have needed treatment at all — a concept called 'overdiagnosis,' meaning the condition was detected but may never have caused problems. Someday this research might help doctors figure out who truly benefits from wearable heart screening, rather than putting more people through treatment they may not need. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether using a smartwatch or fitness tracker to check the patient's heart rhythm could lead to finding an irregular heartbeat that might not actually need treatment.
What's New
PubMed · September 1, 2026
Researchers found that a structured self-management program — where people with chronic conditions like type 2 diabetes learn skills to manage their health day-to-day — led to lasting improvements in sleep, pain, fatigue, and mood, even six months after the program ended, across many different countries. For someone with type 2 diabetes, this matters because managing a long-term condition involves a lot more than just medication — things like energy levels, sleep, and emotional well-being all affect how well someone can stay on top of their health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that among nearly 50,000 people with atrial fibrillation (an irregular heartbeat) who had a procedure called catheter ablation — where doctors use energy to correct the abnormal electrical signals in the heart — certain health factors made it more likely the irregular rhythm would come back. Smoking, gum disease, untreated sleep apnea, and uncontrolled high blood pressure were among the strongest predictors of recurrence, suggesting that managing these conditions alongside the procedure may matter a great deal for long-term success. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a newer heart procedure called pulsed-field ablation — which uses precise bursts of electrical energy to treat atrial fibrillation (an irregular heartbeat) — worked faster and caused fewer cases of a nerve injury that can temporarily affect breathing, compared to an older freezing-based procedure called cryoablation. However, the newer technique did show higher levels of a protein in the blood that can signal minor heart stress, though what that means for patients long-term isn't yet clear. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that for people with atrial fibrillation (an irregular heart rhythm that raises stroke risk) who had recently had a stroke, starting blood-thinning medication soon afterward appeared to be just as safe as waiting longer — with no meaningful difference in repeat strokes, serious bleeding, or death. This matters because doctors have long been unsure about the right timing, and earlier treatment could potentially help prevent another stroke during a vulnerable window. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a newer procedure called pulsed field ablation — which uses targeted electrical pulses to treat atrial fibrillation (an irregular heartbeat) by disabling small areas of heart tissue — works very well at blocking problem signals in the heart, but can sometimes cause side effects including kidney injury and signs of heart muscle stress, especially when more pulses are used. The review looked at several different device designs and found that one year after the procedure, between 55% and 88% of patients stayed free of irregular heart rhythms, depending on the device. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that artificial intelligence models — which can analyze large amounts of patient data and spot complex patterns — were better at predicting stroke risk in people with atrial fibrillation (an irregular heartbeat) than the standard scoring tool doctors currently use. This matters because more accurate predictions could help doctors decide more precisely who truly needs blood thinners to prevent strokes, potentially protecting some people from unnecessary medication side effects while ensuring higher-risk patients get the protection they need. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that a surgical procedure called Cox-Maze IV — which uses heat and freezing energy to create scar tissue in the heart and disrupt the abnormal electrical signals that cause atrial fibrillation (an irregular heartbeat) — helped about 76% of patients stay free from irregular heart rhythms for up to a year when performed alongside other heart surgery. For people with atrial fibrillation that doesn't stop on its own, this suggests the procedure may offer a meaningful chance of relief, especially when heart surgery is already planned for another reason. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that for people with atrial fibrillation (an irregular heartbeat that raises the risk of stroke) who had a small device implanted to close off a pouch in the heart called the left atrial appendage, taking a blood thinner pill after the procedure appeared to be safer than taking two anti-clotting medications together — with lower rates of blood clots forming on the device and fewer serious bleeding episodes. This matters because doctors are still figuring out the best way to protect patients in the weeks right after this procedure, and this analysis combined results from three separate studies involving over 700 patients to get a clearer picture. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that in people with atrial fibrillation (an irregular heartbeat condition), doing moderate, steady-paced aerobic exercise over 12 weeks was more likely to meaningfully lower blood pressure during physical activity than doing short bursts of very intense exercise — with 43% of the steady-exercise group seeing a significant drop in peak blood pressure, compared to only 19% in the high-intensity group. High blood pressure during exercise can put extra strain on the heart, so finding ways to reduce it may matter for people managing atrial fibrillation. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that for people with coronary artery disease who have had a procedure to open blocked heart arteries (called a stent procedure), tailoring blood-thinning medication to each person's individual risk — rather than giving everyone the same standard 12-month regimen — can reduce serious bleeding by roughly 25% to 65%, especially for those already at high risk of bleeding. However, the picture is mixed: shortening the medication course too aggressively in some groups, particularly people who had a recent heart attack, was linked to a higher chance of having another heart attack in at least one study. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
A study found that two different delivery systems used to guide a small implanted device into a part of the heart called the left atrial appendage — a tiny pouch where dangerous blood clots can form in people with atrial fibrillation (an irregular heartbeat) — both worked well, with one newer flexible system achieving a 100% success rate compared to 84% for the standard system, and fewer complications. This matters because the procedure, which reduces stroke risk by sealing off that clot-prone pouch, depends heavily on the tools used to position the device precisely inside the heart. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · September 1, 2026
Researchers found that using a newer type of steerable sheath — a thin, flexible tube that helps guide instruments to the heart during a procedure called ablation (where small areas of heart tissue are treated to correct abnormal electrical signals) — reduced the amount of X-ray exposure patients received during the procedure. The study also found that this tool helped doctors more successfully isolate the specific areas of the heart causing atrial fibrillation (an irregular heartbeat) on the first attempt, which may matter because fewer repeat attempts could mean a smoother procedure. This is early research and hasn't yet changed treatment guidelines.
What's New
The Lancet · August 30, 2026
Researchers found that when studying a heart procedure called catheter ablation — where doctors use energy to disrupt the faulty electrical signals that cause atrial fibrillation (an irregular heartbeat) — some patients who received a fake version of the procedure also reported feeling better. This raises questions about how much of the benefit comes from the procedure itself versus simply believing treatment is working, which matters because it could affect how success is measured for people living with atrial fibrillation. This is early research and hasn't yet changed treatment guidelines.
What's New
The Lancet · August 30, 2026
Researchers found that a procedure called catheter ablation — where doctors use heat or cold energy to scar small areas of heart tissue to stop irregular electrical signals — did not work better than a fake (sham) procedure at improving how people with atrial fibrillation felt and lived their daily lives after 6 months. Atrial fibrillation is an irregular heartbeat that can cause fatigue, shortness of breath, and a fluttery feeling in the chest. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 29, 2026
A study found that using a drug called landiolol to quickly slow down a racing heart in people hospitalized with heart failure and an irregular heartbeat (called atrial fibrillation) worked faster and more effectively than standard treatment — bringing the heart rate down to a safer level within about 1.5 hours compared to 4 hours with usual care. Patients who received this faster heart-rate control also felt less short of breath and had less fluid buildup in their lungs early on, without experiencing dangerous drops in blood pressure. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 25, 2026
Researchers found that for people who had a stroke and also have atrial fibrillation (an irregular heartbeat that raises stroke risk) plus significant plaque buildup in their arteries, adding an antiplatelet drug — like aspirin, which helps prevent blood clots — on top of a blood thinner did not lower the chances of having another stroke or dying, but it did raise the risk of serious bleeding by nearly 50%. This matters because some doctors have wondered whether combining these two types of medication might offer better protection, and this research suggests the added drug may cause more harm than good. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient needs to take both a blood thinner and an aspirin-type medication together, or if just the blood thinner alone would work better to prevent another stroke.
What's New
PubMed · August 21, 2026
Researchers found that for people with atrial fibrillation — an irregular heartbeat that raises stroke risk — who had previously experienced bleeding in the brain, a newer type of blood thinner called a DOAC appeared safer than an older type called a vitamin K antagonist (such as warfarin). Specifically, people taking DOACs had lower rates of a repeat brain bleed, stroke, and death compared to those on the older blood thinner. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
ScienceDaily · August 8, 2026
A large study found that the standard recommendation of 150 minutes of exercise per week — think a brisk 30-minute walk five days a week — may only offer modest protection against serious heart problems like heart attacks or strokes in people with coronary artery disease (a condition where the arteries supplying the heart become narrowed or blocked). Researchers found that much greater benefits appeared when people got closer to 560 to 610 minutes of moderate-to-vigorous activity per week — that's roughly 80 to 90 minutes a day of brisk walking, running, or cycling. People with this condition may want to have a conversation with their doctor about what level of physical activity makes sense for their individual situation.
What's New
PubMed · August 7, 2026
A study found that researchers are testing whether a conversational AI tool — essentially a chatbot that can hold human-like conversations — can help people with atrial fibrillation (an irregular heartbeat that raises the risk of stroke and affects daily life) better manage their condition and feel better overall. Around 480 people with atrial fibrillation will take part over three months, with some using the AI tool and others receiving their usual care, so researchers can compare the two groups. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 6, 2026
Researchers found that a new blood-thinning drug called abelacimab caused less bleeding in people with atrial fibrillation (an irregular heartbeat that raises the risk of stroke) compared to standard blood thinners — and the benefit may have been even greater for people who had never taken a blood thinner before. This matters because bleeding is one of the biggest concerns when treating atrial fibrillation, and a medication that reduces that risk could be meaningful for patients and their doctors. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 4, 2026
Researchers found that finerenone, a medication that blocks certain hormones to protect the heart and kidneys, appeared to reduce the risk of sudden death in people with type 2 diabetes and kidney disease — a finding that stood out across three large studies involving nearly 19,000 people. Sudden death, meaning the heart unexpectedly stops without warning, is one of the most serious risks for people managing both diabetes and kidney problems, so even a modest reduction could be meaningful. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 4, 2026
Researchers found that two different types of electrical shocks used to reset the heart's rhythm in people with atrial fibrillation — an irregular heartbeat that can cause symptoms like fatigue, dizziness, or shortness of breath — worked equally well, with both returning the heart to a normal rhythm about 83–84% of the time after just one shock. This means doctors may have more flexibility in choosing which machine or method they use without worrying that one is clearly better than the other. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 3, 2026
A study found that older patients (75 and up) with atrial fibrillation — an irregular heartbeat that raises the risk of stroke — who had recently received a drug-eluting stent (a small tube placed in an artery to keep it open) may do better on a blood thinner alone rather than combining it with an additional anticlotting medication called clopidogrel, with fewer deaths, heart attacks, strokes, and serious bleeding events observed in that older group. Younger patients in the study didn't show the same difference between the two approaches, suggesting age may play an important role in choosing the right medication strategy. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient should take just an anticoagulant drug like apixaban or rivaroxaban alone, or whether adding clopidogrel to it would be safer for the patient's heart stent.
Guidelines
PubMed · August 1, 2026
Researchers found that people who closely followed a Mediterranean diet — which is rich in vegetables, fruits, whole grains, and healthy fats like olive oil — had a lower risk of serious heart problems like heart attacks or strokes, as well as high blood pressure. The analysis looked at data from more than 1.4 million people across 87 studies, and even small improvements in how closely someone followed the diet were linked to meaningful benefits. This suggests that eating patterns can play an important role in heart health, and people may want to talk with their doctor about how diet fits into their overall care.
What's New
PubMed · August 1, 2026
Researchers found that an irregular heartbeat condition called atrial fibrillation — where the heart quivers instead of beating steadily, which can cause dangerous blood clots — is commonly missed in people who have had a stroke or a 'mini-stroke' (a brief stroke-like episode that goes away quickly). The study found that how often this irregular heartbeat was caught depended heavily on the type of heart-monitoring device used, with some methods detecting it in roughly 1 in 8 patients. This matters because identifying an irregular heartbeat after a stroke could be important for reducing the chances of another stroke down the road. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that people with atrial fibrillation (an irregular heartbeat) who had the condition come back within the first 90 days after a procedure called pulsed field ablation — a newer technique that uses targeted energy to correct abnormal heart rhythms — were nearly nine times more likely to experience it returning again later on. This suggests that early flare-ups after the procedure may be a meaningful warning sign of longer-term trouble, rather than just a temporary hiccup as doctors have sometimes assumed. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · August 1, 2026
Researchers found that for people with atrial fibrillation (an irregular heartbeat that raises the risk of stroke) who also had a procedure to open blocked heart arteries, taking a shorter course of two blood-thinning medications together — just one month instead of twelve — led to fewer serious bleeding events without increasing the risk of death or other dangerous complications like stroke or heart attack. This matters because bleeding is one of the biggest concerns when people with atrial fibrillation need these kinds of heart procedures, and finding a safer way to manage that risk could make a real difference in their care. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether the patient might need to take two blood thinners for only 1 month instead of the usual 12 months after getting a stent, based on new research showing this shorter approach works just as well.
What's New
PubMed · August 1, 2026
Researchers found that colchicine — an anti-inflammatory medication that has long been used for gout — may help reduce the risk of atrial fibrillation (an irregular heartbeat that can raise the risk of stroke) by about 26% in people with heart disease. The study, which pooled results from nearly 38,000 participants across 39 trials, also found reductions in heart attacks and hospitalizations, though no reduction in overall death rates. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.